[Infostock Daily=Reporter Lee Ji-sun] Samsung BioLogics has achieved annual sales of 1 trillion won in nine years since its foundation.
Samsung BioLogics announced on the 26th that it recorded annual sales of 1.1648 trillion won and operating profit of 292.8 billion won last year.
Sales rose 66% year-on-year and operating profit increased 219.3%. Samsung BioLogics won 1.8899 trillion won (1.78 billion dollars) last year, including GSK's 693.7 billion won (627 million dollars) contract.
This is about 2.5 times the sales of 2019. Despite the rapidly changing business environment to COVID-19, support for due diligence and inspections by global regulators through non-face-to-face real-time virtual tours played a positive role.
Sales in the fourth quarter reached a record high of 375.3 billion won, up 36.7 percent from the previous quarter. Samsung BioLogics explained, "This is due to improved factory utilization and some COVID-19 drugs reflected in sales.".
Over the next 10 years, the company plans to secure next-generation growth engines by expanding production capacity and diversifying its business portfolio.
Last year, it opened a global commissioned development (CDO) research and development (R&D) center in San Francisco, USA.
Samsung BioLogics said it has won a total of 47 consignment production (CMO) contracts so far at the '2021 JP Morgan Healthcare Conference' held online this month.
Reporter Lee Ji-sun stockmk2020@gmail.com
